Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. TopoTarget is a biopharmaceutical oncology company focused on the discovery and development of anticancer drugs based on a detailed understanding of molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company is the result of a merger in June 2002, between the Danish company, TopoTarget, and Prolifix, based in Abingdon, UK, and combines extensive clinical experience with a deep understanding of the molecular mechanisms of cancer.